CDSCO Panel Approves Updated Package Insert for Novartis' Ofatumumab Injection
New Delhi:The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the proposal presented by the drug major Novartis for update in package insert for the drug product Ofatumumab solution for injection in pre-filled syringe of 20 mg/0.4 mL with changes in sections of contraindications, warnings and precautions, patient counseling information and instructions for use
This came after the firm presented the proposal for an update in the package insert for the drug product Ofatumumab solution for injection in a pre-filled syringe of 20 mg/0.4 mL based on the U.S. pack insert dated 12 April 2024 with changes in Sections of Contraindications, Warning and Precaution, Patient Counseling Information, and Instructions for Use.
Ofatumumab, a fully human anti-CD20 monoclonal antibody, is a disease-modifying therapy (DMT) approved for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS in adults
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.